Evidence map›Paper›PMID 36560613›Full record

ArticleViruses2022

Comparison of a Prototype SARS-CoV-2 Lateral Flow IMMUNOASSAY with the BinaxNOW

Haydon J Hill, Timsy Uppal, Derrick Hau, Sujata G Pandit, Jose Arias-Umana, Abigail J Foster, Andrew Gorzalski, Kathryn J Pflughoeft, Amanda R Burnham-Marusich, Dana E Reed and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Haydon J HillDepartment of Microbiology and Immunology, Reno School of Medicine, University of Nevada, Reno, NV 89557, USA.ORCID 0000-0002-2602-3273
Timsy UppalDepartment of Microbiology and Immunology, Reno School of Medicine, University of Nevada, Reno, NV 89557, USA.
Derrick HauDepartment of Microbiology and Immunology, Reno School of Medicine, University of Nevada, Reno, NV 89557, USA.
Sujata G PanditDepartment of Microbiology and Immunology, Reno School of Medicine, University of Nevada, Reno, NV 89557, USA.
Jose Arias-UmanaDepartment of Microbiology and Immunology, Reno School of Medicine, University of Nevada, Reno, NV 89557, USA.ORCID 0000-0002-7154-4780
Abigail J FosterDepartment of Microbiology and Immunology, Reno School of Medicine, University of Nevada, Reno, NV 89557, USA.
Andrew GorzalskiNevada State Public Health Laboratory, Reno, NV 89503, USA.ORCID 0000-0002-0268-2039
Kathryn J PflughoeftDxDiscovery Incorporated, Reno, NV 89557, USA.
Amanda R Burnham-MarusichDxDiscovery Incorporated, Reno, NV 89557, USA.
Dana E ReedDepartment of Microbiology and Immunology, Reno School of Medicine, University of Nevada, Reno, NV 89557, USA.
Marcellene A Gates-HollingsworthDepartment of Microbiology and Immunology, Reno School of Medicine, University of Nevada, Reno, NV 89557, USA.
Lynette GumbletonNevada State Public Health Laboratory, Reno, NV 89503, USA.
Subhash C VermaDepartment of Microbiology and Immunology, Reno School of Medicine, University of Nevada, Reno, NV 89557, USA.ORCID 0000-0002-0492-6578
David P AuCoinDepartment of Microbiology and Immunology, Reno School of Medicine, University of Nevada, Reno, NV 89557, USA.
University of Nevada, Reno · USDxDiscovery (United States) · USNevada Division of Public and Behavioral Health · US

Funding

Outreach/Diversity/Pipeline ProjectP20GM103440 · NIGMS · UNIVERSITY OF NEVADA RENO · PI Julia Petereit · 2012 to 2026
$58.0M
NIGMS NIH HHS P20 GM103440
6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus responsible for the COVID-19 pandemic. From the onset of the pandemic, rapid antigen tests have quickly proved themselves to be an accurate and accessible diagnostic platform. The initial (and still most commonly used antigen tests) for COVID-19 diagnosis were constructed using monoclonal antibodies (mAbs) specific to severe acute respiratory syndrome coronavirus (SARS-CoV) nucleocapsid protein (NP). These mAbs are able to bind SARS-CoV-2 NP due to high homology between the two viruses. However, since first being identified in 2019, SARS-CoV-2 has continuously mutated, and a multitude of variants have appeared. These mutations have an elevated risk of leading to possible diagnostic escape when using tests produced with SARS-CoV-derived mAbs. Here, we established a library of 18 mAbs specific to SARS-CoV-2 NP and used two of these mAbs (1CV7 and 1CV14) to generate a prototype antigen-detection lateral flow immunoassay (LFI). A side-by-side analysis of the 1CV7/1CV14 LFI and the commercially available BinaxNOW

Indexed as

COVID-19Antibodies, MonoclonalAntigensCOVID-19 TestingHumansImmunoassayPandemicsSARS-CoV-2Sensitivity and SpecificityAntibodies, MonoclonalAntigensantigen assaysCOVID-19lateral flow immunoassay (LFI)monoclonal antibodies (mAb)SARS-CoV-2

Identifiers

PMID36560613
PMCPMC9786212
OpenAlexW4309845799

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.